A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes

NCT07032688 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: SHR-3167 Injection
DRUG: Insulin Degludec Injection

Sponsor

Jiangsu HengRui Medicine Co., Ltd.